Other Events ·
Charles River Laboratories International, Inc. issued a press release on September 24, 2026, during its Investor Day…
CRLCharles River Laboratories International, Inc.
Charles River Laboratories International, Inc. issued a press release on September 24, 2026, during its Investor Day to outline the 'Pathway to Purpose' strategic vision aimed at modernizing operations and strengthening its scientific portfolio. The company reaffirmed its full-year 2026 guidance, expecting revenue and non-GAAP earnings per share at the upper ends of prior ranges ($11.45). It introduced long-term financial targets through 2030, including a 5%–7% organic revenue CAGR (2027-2030), approximately 24% non-GAAP operating margin, and low-double-digit non-GAAP EPS growth. Additionally, the firm expects over $300 million in cumulative savings from its 'Create the Future' efficiency program between 2027 and 2030. Charles River Laboratories International, Inc. operates in the biotechnology industry, providing essential products and services to accelerate pharmaceutical research and drug development.